Brian T Hill
Overview
Explore the profile of Brian T Hill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
6491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Neelapu S, Jacobson C, Ghobadi A, Miklos D, Lekakis L, Oluwole O, et al.
Blood
. 2023 Feb;
141(19):2307-2315.
PMID: 36821768
In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with...
22.
Sawalha Y, Goyal S, Switchenko J, Romancik J, Kamdar M, Greenwell I, et al.
Blood Adv
. 2023 Feb;
7(13):2983-2993.
PMID: 36809796
To report the activity of venetoclax in patients with relapsed mantle cell lymphoma (MCL), we identified 81 patients treated with venetoclax monotherapy (n = 50, 62%) or in combination with...
23.
Mian A, Wei W, Hamilton B, Winter A, Khouri J, Pohlman B, et al.
Bone Marrow Transplant
. 2023 Feb;
58(5):590-593.
PMID: 36774431
No abstract available.
24.
Wang Y, Jain P, Locke F, Maurer M, Frank M, Munoz J, et al.
J Clin Oncol
. 2023 Feb;
41(14):2594-2606.
PMID: 36753699
Purpose: Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell lymphoma (MCL). This therapy was approved on the basis of the...
25.
Shouse G, Kaempf A, Gordon M, Artz A, Yashar D, Sigmund A, et al.
Blood Adv
. 2023 Feb;
7(14):3516-3529.
PMID: 36735393
Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of response and prevalent toxicities remain problematic. Identifying patients...
26.
Hess B, Giri A, Park Y, Patel K, Link B, Nowakowski G, et al.
Am J Hematol
. 2023 Jan;
98(2):300-308.
PMID: 36588409
Plasmablastic lymphoma (PBL) is a rare entity, commonly associated with immunosuppressed states such as human immunodeficiency virus (HIV) infection or solid organ transplant. The clinical course is characterized by high...
27.
Epperla N, Switchenko J, Bachanova V, Gerson J, Barta S, Gordon M, et al.
Blood Adv
. 2022 Dec;
7(11):2287-2296.
PMID: 36516079
The prognostic relevance of diagnosis to treatment interval (DTI) in patients with newly diagnosed mantle cell lymphoma (MCL) is unknown. Hence, we sought to evaluate the impact of DTI on...
28.
Jalota A, Hershberger C, Patel M, Mian A, Faruqi A, Khademi G, et al.
Blood Adv
. 2022 Nov;
7(17):4690-4700.
PMID: 36399526
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a highly effective treatment option for patients with relapsed/refractory large B-cell lymphoma. However, widespread use is deterred by the development of clinically...
29.
Cortese M, Wei W, Cerdena S, Watkins M, Olson M, Jodon G, et al.
Leuk Lymphoma
. 2022 Nov;
64(1):107-118.
PMID: 36323309
Patients with double- and triple-hit lymphomas (DHL/THL) have inferior outcomes with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), and higher-intensity regimens such as dose-adjusted (DA)-EPOCH-R are standard. Dose-intensification of DA-EPOCH-R...
30.
Hill B, Kahl B
Expert Rev Hematol
. 2022 Sep;
15(9):805-812.
PMID: 36102156
Introduction: Diffuse large B-cell lymphoma (DLBCL) is not a single entity but instead represents a collection of interrelated malignancies having distinct molecular features. Recent multiomics studies have independently identified the...